| NCT ID | Title | Status | Phases | Start Date | Completion Date | Primary Completion Date |
|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | RECRUITING | PHASE3 | 2025-05-30 | 2029-02 | 2029-02 |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | COMPLETED | PHASE2 | 2021-03-29 | 2025-05-14 | 2025-05-14 |
| NCT02065973 | An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 | COMPLETED | PHASE1 | 2014-02 | 2015-12-30 | 2015-12-30 |